Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
JNJ-63709178
i
Other names:
JNJ-63709178, CD123 x CD3 DuoBody, JNJ 63709178, CD123-CD3 DuoBody protein, CNTO 9958, JNJ-9178
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Genmab, J&J
Drug class:
CD3 agonist, CD123 inhibitor
Related drugs:
‹
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
VIR-5818 (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
MK-4002 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
tagraxofusp-erzs (5)
SAR443579 (1)
AFM28 (0)
CD123 targeted CAR-NK (0)
JD023 (0)
JNJ-56022473 (0)
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
VIR-5818 (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
MK-4002 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
tagraxofusp-erzs (5)
SAR443579 (1)
AFM28 (0)
CD123 targeted CAR-NK (0)
JD023 (0)
JNJ-56022473 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
First-in-Human Study of JNJ-63709178, a CD123/CD3 Targeting Antibody, in Relapsed/Refractory Acute Myeloid Leukemia. (PubMed, Clin Transl Sci)
Minimal clinical activity was observed across all cohorts. IV and SC dosing of JNJ-63709178 was associated with suboptimal drug exposure, unfavorable safety profiles, limited clinical activity, and inability to identify a recommended Phase 2 dose.
over 1 year ago
P1 data • Journal
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
JNJ-63709178
3years
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=62, Completed, Janssen Research & Development, LLC | Recruiting --> Completed | N=120 --> 62 | Trial completion date: Oct 2022 --> Mar 2021 | Trial primary completion date: May 2022 --> Mar 2021
3 years ago
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
JNJ-63709178
almost4years
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2020 --> May 2022
almost 4 years ago
Clinical • Trial primary completion date
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
JNJ-63709178
almost5years
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2022 --> Oct 2022
almost 5 years ago
Clinical • Trial completion date
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
JNJ-63709178
almost5years
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=120, Recruiting, Janssen Research & Development, LLC | N=60 --> 120 | Trial completion date: Oct 2021 --> May 2022
almost 5 years ago
Clinical • Enrollment change • Trial completion date
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
JNJ-63709178
almost6years
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=60, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2021 --> Aug 2021 | Suspended --> Recruiting
almost 6 years ago
Clinical • Enrollment open • Trial completion date
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
JNJ-63709178
over6years
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=60, Suspended, Janssen Research & Development, LLC | Trial completion date: Oct 2020 --> Apr 2021
over 6 years ago
Trial completion date
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
CD123 expression
|
JNJ-63709178
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login